Adzynma’s Phase 3 Clinical Trial and Approval
Björn Mellgård, MD, PhD, Vice President, Global Program Lead, Rare Genetics and Hematology, Takeda, discusses the steps taken for Adzynma to get FDA approved for patients with congenital thrombotic thrombocytopenic purpura (cTTP).